-
Posted by
Two Blokes Jul 15 -
Filed in
Stock
-
1 view
GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights over traditional panel testing. The company achieved a significant turnaround, becoming cash flow positive in Q4 2024 and Q1 2025 after years of net losses. Strategic restructuring, including shutting down Sema4's reproductive health unit, streamlined costs and sharpened focus on WGS's core strengths.
